MYMD Insider Trading

Insider Ownership Percentage: 2.12%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

MyMD Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at MyMD Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k$0$100kTotal Insider BuyingTotal Insider Selling

MyMD Pharmaceuticals Share Price & Price History

Current Price: $0.35
Price Change: Price Decrease of -0.01 (-2.78%)
As of 03/31/2025 01:00 AM ET

This chart shows the closing price history over time for MYMD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.36Closing price on 03/31/25:

MyMD Pharmaceuticals Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for MyMD Pharmaceuticals (NASDAQ:MYMD)

9.64% of MyMD Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MYMD by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500k$0$500kTotal InflowsTotal Outflows
MyMD Pharmaceuticals logo
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Read More on MyMD Pharmaceuticals

Today's Range

Now: $0.35
Low: $0.34
High: $0.37

50 Day Range

MA: $0.58
Low: $0.35
High: $1.19

52 Week Range

Now: $0.35
Low: $1.75
High: $63.90

Volume

150,273 shs

Average Volume

134,123 shs

Market Capitalization

$829,500.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15

Who are the company insiders with the largest holdings of MyMD Pharmaceuticals?

MyMD Pharmaceuticals' top insider investors include:
  1. Paul Rivard (Insider)
Learn More about top insider investors at MyMD Pharmaceuticals.